Vanguard Group
AARD

Vanguard Group’s Aardvark Therapeutics AARD Stock Holding History

Vanguard Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.42M Buy
717,430
+161,709
+29% +$2.02M ﹤0.01% 2991
2025
Q3 		$7.39M Buy
555,721
+94,744
+21% +$1.07M ﹤0.01% 3134
2025
Q2 		$6.23M Buy
460,977
+295,486
+179% +$3.04M ﹤0.01% 3134
2025
Q1 		$1.24M Buy
+165,491
New +$1.86M ﹤0.01% 3648

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group's AARD Position: Q4 2025 in Review

Vanguard Group increased its Aardvark Therapeutics (AARD) stake by 29% in Q4 2025, buying an estimated $2.02M and bringing the position to 717,430 shares worth $9.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2991.

Vanguard Group first reported a position in AARD in Q1 2025 and has held it in 4 quarters since. 66 funds tracked by Wall St. Rank hold AARD as of Q4 2025.

  • Vanguard Group held 717,430 shares of Aardvark Therapeutics worth $9.42M as of Q4 2025.
  • Vanguard Group bought 161,709 Aardvark Therapeutics shares in Q4 2025, an estimated $2.02M.
  • Aardvark Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2991 holding.
  • Vanguard Group first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 66 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.